



國家衛生研究院
National Health Research Institutes


Method and composition for decreasing the psychotomimetic side effect and addictive disorder of ketamine

Invention Description

The present invention relates to a method for decreasing the psychotomimetic side effects and addictive disorders of ketamine by using betaine or a betaine metabolite N,N-dimethylglycine (DMG).

Mechanism of action (MOA)

Betaine and DMG, recognized as the generally recognized as safe, are partial agonists at NMDA receptor glycine binding site.



Indications and Usage

Depression
Bipolar disorder
Post-traumatic stress disorder
Obsessive-Compulsive Disorder
Pain
Abuse disorders
Parkinson disease
Amyotrophic lateral sclerosis

Patent granted

Taiwan, Japan,
US, Canada,
Israel

Application

Europe, China

Adjusted
expiration

2038-01-01